One Year of a Single Drug Delayed Rheumatoid Arthritis by Up to Four Years, Trial Finds

For the first time, researchers have shown that a single year of drug treatment can stave off rheumatoid arthritis for years in people at high risk of developing the painful autoimmune disease — a finding that could shift the field from managing the condition toward preventing it altogether.

In a trial led by researchers at King's College London and published in The Lancet Rheumatology, patients who received 12 months of the biologic drug abatacept took significantly longer to develop rheumatoid arthritis than those given a placebo, with the onset of disease delayed by up to four years beyond the treatment period. Crucially, the protective effect persisted well after the injections stopped.

The study recruited 213 people who tested positive for anticitrullinated protein antibodies and reported joint pain known as arthralgia — markers that place them at elevated risk of progressing to full rheumatoid arthritis. Participants were randomly assigned to receive 52 weekly subcutaneous injections of 125 milligrams of abatacept or a placebo, with 110 patients in the treatment group and 103 in the placebo group, followed by additional months of observation.

Abatacept works by targeting the activation of immune cells called T cells, dialing back the misfired immune response that drives rheumatoid arthritis. The drug was well tolerated in the trial, and researchers found the benefit was most pronounced among patients with specific autoantibody profiles, suggesting it may one day be possible to identify exactly who stands to gain the most from early intervention.

The implications are significant because, while effective therapies exist for people who already have established rheumatoid arthritis, there is currently no licensed treatment that can prevent the disease from taking hold in those at risk. Rheumatoid arthritis affects millions worldwide and can cause irreversible joint damage, disability and chronic pain if left unchecked. Heading it off, even temporarily, could spare patients years of symptoms and complications.

The work builds on an earlier trial led by King's researchers in 2024 and represents a step toward what rheumatologists have long sought: a way to interrupt the disease before it starts. Researchers cautioned that a one-year course of treatment is not a permanent cure and that more work is needed to determine the optimal timing and duration of therapy. Still, the results offer the strongest evidence yet that the trajectory toward rheumatoid arthritis is not inevitable — and that the right drug, given early, can buy patients years of healthy time.